DBVT dbv-technologies.com: Long-Term Debt to Capital Coefficient

Symbol and logo of brand DBV Technologies (DBVT)

This daily price chart for DBV Technologies S.A. (DBVT) illustrates the performance of the company developing innovative Viaskin patches to combat food allergies, where the primary driver is FDA approval for the pediatric peanut drug. The environmental profile is based on bio-waste disposal in laboratories, and the current metric stands at 0.04. However, the risk of losing market share persists due to competition from simpler oral treatment methods.

DBVT - dbv-technologies.com Long-Term Debt to Equity over the range 07/04/2022 - 10/28/2026

Comprehensive metric breakdowns and analytics for DBV Tech (DBVT)

- price and consensus price forecast:
Quote Chart DBV Technologies SA|DBVT - Analyst Consensus Forecast
- market capitalization data:
Market Value DBV Technologies S.A.|DBVT - Enterprise Value
- book capitalization data:
Book Value per Share DBV Technologies|DBVT - Company Book Value|Market Value to Book Value dbv-technologies.com|DBVT - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio DBV Technologies S.A.|DBVT - Long-Term Debt to Capital|Short-Term Debt to Capital DBV Technologies SA|DBVT - Company Total Debt|Debt to Net Assets Ratio DBV Technologies S.A.|DBVT - Company Long-Term Debt|Short-Term Debt Volume DBV Technologies
Initial company analysis:dbv-technologies.com
Core merchandise of DBV Tech

By advancing patch technologies and optimizing international component logistics, DBV Technologies S.A. requires a precise balance between biolaboratory investments and debt load. An analysis of the long-term debt-to-equity structure allows for an assessment of the ratio of liabilities with maturities exceeding one year to equity, determining the company's ability to withstand operational shocks and the extent to which its financial stability depends on borrowed capital.

Direct competitors

Long-Term Liabilities to Equity Krystal Biotech Inc|Apogee Pharma (APGE) - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient Arcutis Corp (ARQT)|Long-Term Debt to Capital VCEL (Vericel Corporation)|orukatx.com - Long-Term Debt to Capital|Long-Term Debt to Equity Sanara (SMTI)|SLSN: Long-Term Debt to Capital Coefficient|DERM (journeymedicalcorp.com) - Long-Term Debt to Equity|Forte Biosciences Inc (FBRX) - Long-Term Debt to Equity Ratio|EMPG (Empro Group Inc) - Long-Term Debt to Capital|Long-Term Debt to Capital sol-gel.com (SLGL)|AXIL Brands, Inc. (AXIL) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient MDCX (Medicus Pharma Ltd)|Long-Term Debt to Equity VRCA|Hoth Therapeutics Inc. - Ratio of Long-Term Indebtedness to Capital|Biofrontera Inc - Long-Term Debt to Equity|VYNE - Long-Term Debt to Capital|sonomapharma.com - Long-Term Debt to Capital|QNRX (Quoin Pharmaceuticals Ltd.) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Azitra Corp (AZTR)|Long-Term Debt to Capital Ratio Dermata Corp|Long-Term Debt to Capital Elevai Labs Inc. ELAB|Long-Term Debt to Capital Ratio revance.com (RVNC)